Skip to main
OMCL

Omnicell (OMCL) Stock Forecast & Price Target

Omnicell (OMCL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Omnicell is positioned to be a key player in the healthcare automation and analytics industry, particularly in the pharmacy and nursing care delivery space. The company's strategic focus on equipping and empowering healthcare providers to improve patient care and outcomes while reducing administrative tasks is likely to drive demand for its products and services. With a strong presence in the US, Omnicell has a solid foundation for growth, and the recent launch of Titan XT, coupled with its cloud-based medication management platform OmniSphere, is expected to generate significant revenue and margin expansion over the next few years. The company also has a stable financial position with a healthy cash flow and manageable debt.

Bears say

Omnicell is set for long-term success with its introduction of its cloud-based medication management platform, OmniSphere, and its expansion of the XT automated dispensing system with Titan XT, which integrates with OmniSphere. With its subscription-based pricing model and ability to provide enterprise-wide visibility and control of medication inventory management, the company is poised for increased recurring revenue and improved margins in the future. Additionally, Omnicell's focus on incremental releases and continuous sales motion allows for faster revenue conversion and implementations, reducing the impact of a traditional 10-year replacement cycle.

Omnicell (OMCL) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omnicell and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omnicell (OMCL) Forecast

Analysts have given Omnicell (OMCL) a Buy based on their latest research and market trends.

According to 5 analysts, Omnicell (OMCL) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omnicell (OMCL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.